📰 [PressRelease] – MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the EBMT.
👉 Read the press release: www.maatpharma.com/march-23-202...
@theebmt.bsky.social
#Cancer #Hematology #AlloHCT #Microbiome #EBMT26
🧬 Even fully HLA-matched transplants can diverge in outcomes.
A study found SNPs in HLA-DOA/DOB linked to survival and GvHD after cord blood transplantation — genes that regulate peptide editing by HLA-DM.
Matching classical alleles isn’t enough; the editors matter too.
#AlloHCT #Genomics
Despite the widespread clinical practice of inducing CR before #alloHCT in patients with R/R #AML, findings from the ASAP trial challenge this standard, with evidence showing that genetics, not remission status, determine overall survival after #transplant: ow.ly/eiu450Xgxxi
#HemeSky #leukemia
Proud to share that MaaT013 (Xervyteg®) clinical data were featured in the latest special issue on acute Graft-versus-Host Disease (#aGvHD) in Current Opinion in Immunology.
🔗Open-access article here: sciencedirect.com/science/arti...
#AlloHCT #Hematology
"God created all diseases except GvHD, that we created" Hillard Lazarus
Transplanters carry guilt of poor patient outcomes and NRM.
The type of cGVHD 👇 reminds me why I vowed NEVER to use tac/mtx again. With ptCY & other data IMO it is no longer acceptable.
#GvHD #alloHCT
Explore the latest ASTCT evidence-based guidelines for #alloHCT in severe aplastic anemia (SAA). Key updates include graft source preferences, expanded donor options and refined #GVHD prophylaxis. Read more: t.co/iNKZB8J2ir #MedSky
